Prof Wojciech Jurczak speaks to ecancer about the results from the BRUIN CLL-313 trial, which evaluated pirtobrutinib in treatment-naïve patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL), presented at ASH 2025.

Prof Jurczak reports that pirtobrutinib significantly improved progression-free survival (PFS) compared to bendamustine plus rituximab, with a 24-month PFS rate of 93.4% for pirtobrutinib versus 70.7% for BR. Pirtobrutinib also demonstrated consistent PFS benefits across key subgroups, including those with mutated or unmutated IGHV.

He highlights that pirtobrutinib had a manageable safety profile with low rates of treatment discontinuation and atrial fibrillation/flutter. Despite some immature overall survival data, a trend favouring pirtobrutinib was observed, supporting its potential as a new standard-of-care treatment for untreated CLL/SLL, especially in older patients.

Click here for more expert commentary on this topic.